Evidence map›Paper›PMID 33527751›Full record

Observational studyPhysiological reports2021

Timing of VV-ECMO therapy implementation influences prognosis of COVID-19 patients.

Raphaël Giraud, David Legouis, Benjamin Assouline, Amandine De Charriere, Dumeng Decosterd, Marie-Eve Brunner, Mallory Moret-Bochatay, Thierry Fumeaux, Karim Bendjelid

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Evaluating factors associated with the use of extracorporeal membrane oxygenation in major trauma - an analysis of the TraumaRegister DGUEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Raphaël GiraudIntensive Care Unit, Geneva University Hospitals, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-5956-8643
David LegouisIntensive Care Unit, Geneva University Hospitals, Geneva, Switzerland.
Benjamin AssoulineIntensive Care Unit, Geneva University Hospitals, Geneva, Switzerland.
Amandine De CharriereIntensive Care Unit, Geneva University Hospitals, Geneva, Switzerland.
Dumeng DecosterdIntensive Care Unit, Réseau Hospitalier Neuchâtelois, Site de Pourtalès, Neuchatel, Switzerland.
Marie-Eve BrunnerIntensive Care Unit, Réseau Hospitalier Neuchâtelois, Site de Pourtalès, Neuchatel, Switzerland.
Mallory Moret-BochatayIntensive Care Unit, Groupement Hospitalier de l'Ouest Lémanique, Hôpital de zone de Nyon, Nyon, Switzerland.
Thierry FumeauxFaculty of Medicine, University of Geneva, Geneva, Switzerland.
Karim BendjelidIntensive Care Unit, Geneva University Hospitals, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-7921-7207
University of Geneva · CHHospital Neuchâtel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrent knowledge on the use of extracorporeal membrane oxygenation (ECMO) in COVID-19 remains limited to small series and registry data. In the present retrospective monocentric study, we report on our experience, our basic principles, and our results in establishing and managing ECMO in critically ill COVID-19 patients.

methodsA cohort study was conducted in patients with severe acute respiratory distress syndrome (ARDS) related to COVID-19 pneumonia admitted to the ICU of the Geneva University Hospitals and supported by VV-ECMO from March 14 to May 31. The VV-ECMO implementation criteria were defined according to an institutional algorithm validated by the local crisis unit and the Swiss Society of Intensive Care Medicine.

resultsOut of 137 ARDS patients admitted to our ICU, 10 patients (age 57 ± 4 years, BMI 31.5 ± 5 kg/m

conclusionThe present results suggest that VV-ECMO can be safely utilized in appropriately selected COVID-19 patients with refractory hypoxemia. The main information for clinicians is that late VV-ECMO therapy (i.e., beyond the seventh day of mechanical ventilation) seems futile.

Indexed as

COVID-19Extracorporeal Membrane OxygenationFemaleHumansMaleMiddle AgedRespiration, ArtificialSurvival AnalysisTime FactorsARDSCOVID-19 pandemicVV-ECMO

Identifiers

PMID33527751
PMCPMC7851435
OpenAlexW3128686564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.